Novartis' Genoptix Licenses Trovagene Marker for AML Services
December 20, 2012
Novartis' Genoptix Licenses Trovagene Marker for AML Services
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genoptix Joins Growing List of Companies Licensing TrovaGene's NPM1 for AML Testing
January 2, 2013 / Pharmacogenomics Reporter - Trovagene Licenses Leukemia Marker to Quest Diagnostics
September 13, 2012 / GenomeWeb Daily News - Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer
April 26, 2013 / GenomeWeb Daily News - Genoptix Offers Targeted Sequencing on Ion PGM to Guide Treatment Decisions for Metastatic Melanoma
March 28, 2012 / Clinical Sequencing News - TrovaGene Licenses SF3B1 Mutations, Plans LDT
January 3, 2012 / GenomeWeb Daily News